| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 530387100 |
Immunoglobulin, antibody, or fragment thereof, other than immunoglobulin antibody, or fragment thereof that is conjugated or adsorbed
| 1390 |
| 530391100 |
Monoclonal or polyclonal antibody or immunoglobulin or fragment thereof that is conjugated or adsorbed (e.g., adsorbed to a solid support, etc.)
| 186 |
| 530394000 |
Beta globulins, e.g., transferrin, etc. | 4 |
| 20110294988 | Purification Process - A process for purifying a transferrin solution and the product of the purification process. A process for producing transferrin and the product of the production process. Use of the transferrin in cell culture, as a pharmaceutical ingredient, as a pharmaceutical product and in a cell culture medium. | 12-01-2011 |
| 20120004398 | Method for Uses of Protein Precursors as Prodrugs - The present invention provides compositions useful as prodrugs and methods for making the same. The compositions include a fusion protein having a first delivery domain and a second protein precursor domain linked together via a linker sequence. The delivery domain is a protein capable of facilitating entry to a target cells via the endocytotic pathway, such as transferrin. The protein precursor is a prohormone or a profactor, such as proinsulin. Methods of this invention include the steps of selecting a protein suitable as the delivery domain, constructing a vector to encode the fusion protein, and expressing the fusion protein in a suitable expression host. | 01-05-2012 |
| 20120296071 | TRANSFERRIN FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF AUTOIMMUNE DISEASES - The present invention describes pharmaceutical compositions containing APOTf for use in preventing (or delaying the onset) and treating autoimmune diseases. Based on the experimental data obtained, the molecule has the surprising capacity to favourably modify the immune response profile both in vitro and in vivo. | 11-22-2012 |
| 20160039907 | PROTEIN FOLDING AND METHODS OF USING SAME - The instant disclosure provides a microscale method for providing correctly folded, and assembled biologically active proteins in an efficient and shorted time frame, compared to conventional protein production techniques. Proteins produced from inclusion bodies and other aggregated protein sources are provided. Microscale production of correctly folded and assembled class I MHC protein and complexes thereof are also provided for, as well as for high throughput production for use in epitope discovery protocols. Microscale production of complex proteins from protein aggregates and preparations containing protein aggregates is provided that requires less than 24 hours of processing time. | 02-11-2016 |
| 530392000 |
Alpha globulins, e.g., ceruloplastin, haptoglobins, etc. | 3 |
| 20100113754 | METHOD FOR PRODUCING ANTITHROMBIN COMPOSITION - The provision of an antithrombin composition having a desired α-form content rate or β-form content rate is required. The invention provides a process for producing an antithrombin composition having a desired α-form content rate or β-form content rate which is prepared by contacting an antithrombin-containing aqueous solution with a Cellufine Sulfate chromatography carrier. | 05-06-2010 |
| 20140148585 | METHOD FOR PURIFYING PROTEIN - The present invention relates to protein purification. More particularly, a method for directly recovering an objective protein from a protein composition and purifying a protein with a desired quality in a rapid and efficient manner is provided. Further, a rapid purification method capable of efficiently removing impurities included in the protein composition is provided. Therefore, compared to the conventional purification methods, quality and yield of the protein can be remarkably improved. | 05-29-2014 |
| 20120253022 | METHOD OF REMOVING PROTEIN-BOUND DELETERIOUS SUBSTANCES DURING EXTRACORPOREAL RENAL REPLACEMENT TREATMENT - The invention is directed to a method of removing a deleterious substance bound to a protein in blood of a patient by introducing a displacer substance into the blood under conditions in which the displacer substance replaces deleterious substance bound to the protein, thereby resulting in additional unbound deleterious substance in the blood, and removing unbound deleterious substance from the blood by extracorporeal renal replacement treatment. | 10-04-2012 |
